1. Home
  2. PRPO vs MBIO Comparison

PRPO vs MBIO Comparison

Compare PRPO & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRPO
  • MBIO
  • Stock Information
  • Founded
  • PRPO N/A
  • MBIO 2015
  • Country
  • PRPO United States
  • MBIO United States
  • Employees
  • PRPO N/A
  • MBIO N/A
  • Industry
  • PRPO Biotechnology: Laboratory Analytical Instruments
  • MBIO Biotechnology: Pharmaceutical Preparations
  • Sector
  • PRPO Industrials
  • MBIO Health Care
  • Exchange
  • PRPO Nasdaq
  • MBIO Nasdaq
  • Market Cap
  • PRPO N/A
  • MBIO 4.7M
  • IPO Year
  • PRPO N/A
  • MBIO N/A
  • Fundamental
  • Price
  • PRPO $11.18
  • MBIO $1.70
  • Analyst Decision
  • PRPO
  • MBIO
  • Analyst Count
  • PRPO 0
  • MBIO 0
  • Target Price
  • PRPO N/A
  • MBIO N/A
  • AVG Volume (30 Days)
  • PRPO 9.8K
  • MBIO 805.1K
  • Earning Date
  • PRPO 08-12-2025
  • MBIO 08-12-2025
  • Dividend Yield
  • PRPO N/A
  • MBIO N/A
  • EPS Growth
  • PRPO N/A
  • MBIO N/A
  • EPS
  • PRPO N/A
  • MBIO N/A
  • Revenue
  • PRPO $20,029,000.00
  • MBIO N/A
  • Revenue This Year
  • PRPO N/A
  • MBIO N/A
  • Revenue Next Year
  • PRPO N/A
  • MBIO N/A
  • P/E Ratio
  • PRPO N/A
  • MBIO N/A
  • Revenue Growth
  • PRPO 26.67
  • MBIO N/A
  • 52 Week Low
  • PRPO $3.90
  • MBIO $0.89
  • 52 Week High
  • PRPO $11.80
  • MBIO $31.00
  • Technical
  • Relative Strength Index (RSI)
  • PRPO 58.62
  • MBIO 31.47
  • Support Level
  • PRPO $10.82
  • MBIO $1.01
  • Resistance Level
  • PRPO $11.70
  • MBIO $1.07
  • Average True Range (ATR)
  • PRPO 0.57
  • MBIO 0.07
  • MACD
  • PRPO -0.15
  • MBIO -0.02
  • Stochastic Oscillator
  • PRPO 52.31
  • MBIO 12.82

About MBIO Mustang Bio Inc.

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

Share on Social Networks: